Secondary Analysis of a Randomized Controlled Trial of Adjuvant Chemotherapy by PSA Response Following Radiotherapy
In brief
After radiation, PSA above 0.2 linked chemo to 41% lower disease-free event hazard
In a secondary analysis of a randomized trial, men whose post-radiation PSA exceeded 0.2 ng/mL had a lower hazard of disease-free survival events with adjuvant chemotherapy; no such association appeared at lower PSA levels. The analysis found no association with distant metastasis or overall survival, and the treatment effect did not significantly differ by PSA group, so prospective confirmation is needed.
- Journal
- Cancer medicine (Q1)
- Published
- 1 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Stephen Andrew Mihalcik, Meredith M Regan, Seth A Rosenthal, Glenn J Bubley, Kenneth J Pienta, Leonard G Gomella, et al.
- PMID
- 43053607
- DOI
- 10.1002/cam4.71910
Why clinicians should know about it
- Picked for Urology (top studies of the week, 22 November 2026): PSA response analysis addresses prostate cancer treatment intensification
Abstract
BACKGROUND: NRG Oncology RTOG 9902 was a randomized controlled trial of the addition of adjuvant chemotherapy (paclitaxel, oral etoposide, estramustine) to long-course androgen suppression and radiation for patients with high-risk prostate cancer. The trial closed early due to excess toxicity and found no benefit to chemotherapy at a median follow-up of 9.2 years. METHODS: Immediate post-radiation PSA status was dichotomized at ≤ 0.2 ng/mL. Landmark analysis redefined starting times for disease-free survival (DFS), time to distant metastasis (TDM), and overall survival (OS) at 36 weeks post-radiation, when planned chemotherapy was complete. Exclusion criteria included non-receipt of radiation or assigned chemotherapy and pre-landmark DFS events or loss to follow-up. Hazard ratios (HR), 95% confidence intervals, and PSA-by-treatment interaction estimated by Cox or competing-risks regression. FINDINGS: Of 333 patients analyzed: 190 without and 143 with chemotherapy. Chemotherapy was associated with improved DFS for patients with PSA > 0.2 (HR 0.59, 0.38-0.91), but not for those with PSA ≤ 0.2 (HR 0.94, 0.60-1.46), interaction p = 0.13. There was no association with chemotherapy relative to post-RT PSA for either TDM or OS. INTERPRETATION: This analysis suggests that men with a post-radiation PSA > 0.2 may benefit from treatment intensification with adjuvant chemotherapy. Prospective trials adapting treatment by PSA response are indicated. TRIAL REGISTRATION: Trial Number: NCT00004054 (ClinicalTrials.gov).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.